What exactly is Lilly buying with this thing, Madison. So Lilly is buying into this fast growing psychedelic space, which was once really on the fringes of drug development, but has gotten a lot more interesting and a lot more interest from drug makers over the last year or so. There are now a couple of companies that are nearing potentially FDA approval.They're in late stages of testing. AtaiBeckley is moving into late stages of testing. They have their lead drug is called BPL zero zero three.It's actually ...

Lily says that it is acquiring psychedelic drug developer Tai Beckley. And Lily will pay $675 in cash or $2.8% billion upfront and another1 billion if certain developmental and regulatory milestones are met. And so a Tai Beckley, their lead drug is related to the psychedelic drug DMT.And the company's testing it for treatment resistant depression. And it's a nasal spray that's a little bit like um J&J's drug spado. So it's administered in a clinic and then patients are monitored for a couple hours and again ...